Analysts Comment on Pfizer (PFE) Following Torcetrapib News

StreetInsider.com (subscription) - Birmingham,MI,USA
... COX-2 Celebrex was also associated with some evidence of
increased cardiovascular risk (December 17, 2004); and
Biogen-Idec and the removal of Tysabri from the ...

Specialty drugs seen driving up premiums
Boston Globe - United States
... for Biogen Idec Inc., said the steep price of specialty drugs
like the Cambridge company's multiple sclerosis treatments,
Avonex and Tysabri, is justified. ...

Gilead Sciences to Present at the NASDAQ 18th Investor Program and ...
Financial News USA (press release) - La Puente,CA,USA
... BIIB) hit a new 52-week high Friday after analysts reaffirmed
positive ratings for the company, citing its multiple sclerosis drug
Tysabri and development ...